To assess the safety of sub-urothelial injection of durvalumab and examine the impact on tissue and circulating immune cell populations.
The patients were chemotherapy and immunotherapy naïve (bacille Calmette-Guérin allowed) with non-metastatic muscle-invasive bladder cancer or non-muscle-invasive bladder cancer planned for radical cystectomy (RC).